TransMedics Group (TMDX) Projected to Post Earnings on Thursday

TransMedics Group (NASDAQ:TMDX) is expected to post its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect the company to post earnings of $0.50 per share and revenue of $183.7870 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.32). TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The firm had revenue of $173.93 million during the quarter, compared to analyst estimates of $174.44 million. During the same period in the previous year, the company posted $0.70 EPS. TransMedics Group’s revenue for the quarter was up 21.2% compared to the same quarter last year. On average, analysts expect TransMedics Group to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

TransMedics Group Price Performance

TransMedics Group stock opened at $71.20 on Thursday. The company has a market capitalization of $2.46 billion, a price-to-earnings ratio of 16.18 and a beta of 1.89. The company has a current ratio of 6.74, a quick ratio of 6.19 and a debt-to-equity ratio of 1.70. TransMedics Group has a 12 month low of $60.10 and a 12 month high of $156.00. The stock’s 50 day moving average is $71.37 and its 200-day moving average is $103.42.

Insider Activity at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the transaction, the director directly owned 16,642 shares in the company, valued at approximately $1,249,148.52. The trade was a 36.64% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Royal Bank of Canada increased its stake in shares of TransMedics Group by 47.9% in the 1st quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock valued at $1,788,000 after purchasing an additional 8,604 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of TransMedics Group by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock worth $1,314,000 after buying an additional 868 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of TransMedics Group by 20.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after buying an additional 86,721 shares during the last quarter. Russell Investments Group Ltd. lifted its position in shares of TransMedics Group by 13.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company’s stock worth $1,059,000 after buying an additional 938 shares during the last quarter. Finally, M&T Bank Corp acquired a new stake in TransMedics Group in the second quarter valued at about $209,000. 99.67% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Wall Street Zen downgraded shares of TransMedics Group from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Zacks Research lowered shares of TransMedics Group from a “hold” rating to a “strong sell” rating in a research report on Monday, July 6th. TD Cowen reiterated a “buy” rating and issued a $120.00 price target on shares of TransMedics Group in a research report on Wednesday, July 1st. Needham & Company LLC cut their price target on TransMedics Group from $174.00 to $142.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Finally, Piper Sandler reissued an “overweight” rating on shares of TransMedics Group in a research report on Wednesday. Six investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, TransMedics Group has a consensus rating of “Hold” and an average target price of $134.50.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.